Clinical Trial Update: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing TQB2450 plus anlotinib hydrochloride versus paclitaxel for injection in triple-negative breast cancer is ongoing, with status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Anlotinib hydrochloride capsule (Anlotinib hydrochloride)
• Paclitaxel for Injection (Albumin-bound) (Paclitaxel (Albumin-bound))
• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: UNKNOWN